Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

Joining the PARty: PARP Regulation of KDM5A during DNA Repair (and Transcription?)

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Poly(ADP-ribose) binding and macroH2A mediate recruitment and functions of KDM5A at DNA lesions

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Functional Aspects of PARP1 in DNA Repair and Transcription

PARP1: Liaison of Chromatin Remodeling and Transcription

Temporal regulation of acetylation status determines PARP1 role in DNA damage response and metabolic homeostasis

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Transcriptional Roles of PARP1 in Cancer

The dynamics and Regulation of PARP1 and PARP2 in response to DNA damage and during replication

Molecular Pathways: Targeting PARP in Cancer Treatment

The FHA and BRCT Domains Recognize ADP-ribosylation During DNA Damage Response.

PDHE1α in DNA Damage Repair: a Critical Chromatin Acetylation Regulator

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics

Functions of Poly(adp-Ribose) Polymerase (PARP) in DNA Repair, Genomic Integrity and Cell Death

Epigenetic Insights on PARP-1 Activity in Cancer Therapy

The expanding universe of PARP1-mediated molecular and therapeutic mechanisms

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

A Chromatin Localization Screen Reveals Poly (ADP Ribose)-Regulated Recruitment of the Repressive Polycomb and NuRD Complexes to Sites of DNA Damage.

Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis